Amundi Asset Management US’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | $30.5M | Sell |
216,007
-1,700
| -0.8% | -$240K | 0.02% | 558 |
|
|
2020
Q4 | $28.3M | Sell |
217,707
-32,294
| -13% | -$4.2M | 0.02% | 541 |
|
|
2020
Q3 | $36.4M | Buy |
250,001
+20,412
| +9% | +$2.97M | 0.04% | 401 |
|
|
2020
Q2 | $34M | Buy |
229,589
+53,155
| +30% | +$7.87M | 0.04% | 394 |
|
|
2020
Q1 | $19.2M | Sell |
176,434
-24,678
| -12% | -$2.69M | 0.03% | 415 |
|
|
2019
Q4 | $23.2M | Buy |
201,112
+22,721
| +13% | +$2.62M | 0.03% | 511 |
|
|
2019
Q3 | $14.3M | Buy |
178,391
+31,958
| +22% | +$2.57M | 0.02% | 611 |
|
|
2019
Q2 | $10.6M | Sell |
146,433
-3,226
| -2% | -$234K | 0.01% | 767 |
|
|
2019
Q1 | $14M | Buy |
149,659
+16,733
| +13% | +$1.56M | 0.02% | 629 |
|
|
2018
Q4 | $9.69K | Buy |
132,926
+4,697
| +4% | +$342 | 0.01% | 668 |
|
|
2018
Q3 | $11.2M | Sell |
128,229
-8,542
| -6% | -$748K | 0.01% | 707 |
|
|
2018
Q2 | $13.5M | Buy |
136,771
+33,869
| +33% | +$3.34M | 0.02% | 641 |
|
|
2018
Q1 | $12.3M | Sell |
102,902
-27,000
| -21% | -$3.22M | 0.02% | 628 |
|
|
2017
Q4 | $16.5M | Buy |
129,902
+34,330
| +36% | +$4.36M | 0.03% | 528 |
|
|
2017
Q3 | $11.2M | Sell |
95,572
-51,622
| -35% | -$6.07M | 0.04% | 290 |
|
|
2017
Q2 | $11.7M | Buy |
147,194
+59,938
| +69% | +$4.78M | 0.04% | 292 |
|
|
2017
Q1 | $4.47M | Buy |
+87,256
| New | +$4.47M | 0.02% | 424 |
|
|
2015
Q4 | – | Sell |
-632,698
| Closed | -$50.8M | – | 546 |
|
|
2015
Q3 | $50.8M | Buy |
632,698
+2,569
| +0.4% | +$206K | 0.21% | 124 |
|
|
2015
Q2 | $75.5M | Buy |
630,129
+145,305
| +30% | +$17.4M | 0.28% | 100 |
|
|
2015
Q1 | $50.6M | Buy |
484,824
+1,611
| +0.3% | +$168K | 0.18% | 144 |
|
|
2014
Q4 | $46.9M | Buy |
483,213
+158,926
| +49% | +$15.4M | 0.17% | 154 |
|
|
2014
Q3 | $25.3M | Buy |
+324,287
| New | +$25.3M | 0.1% | 215 |
|